Important matters:
Vilishibo-B (09887): Phase II clinical study of Vilisin® (opatisumimab, PD-L1/4-1BB bispecific antibody, LBL-024) for first-line treatment of ESCC has entered an expansion phase
Hengrui Pharmaceutical (01276): Application for drug marketing license for HRG2010 capsules accepted
Leader Education (01449) and NeuralFin agree to establish a strategic partnership in the field of artificial intelligence (AI) education
Shanghai Pharmaceutical (02607) plans to sell 51% of Shanghai Shangyao Xintedong Ammonium Pharmacy
Baoji Pharmaceutical-B (02659): KJ015 injection (anti-HER2 bispecific antibody subcutaneous preparation) clinical trial application obtained US FDA approval
Changfeng Pharmaceutical (02652): ICF001 expands the scope of indications after receiving implied approval for clinical trials from the State Drug Administration
Xiaopeng Group-W (09868): Pengheng received US$600 million subscription from IDG Capital, Alibaba, Tencent and Gao Rong Venture Capital to purchase Pengxing A series preferred shares
Operating performance:
Yunying Valley Technology (03310) released interim results, with revenue of 318 million yuan to further cultivate the brand's AMOLED display driver chip market
Fayu-B (02256) successfully commercialized R&D support for the core drug Berger® in the first half of the year
Easy Health (02661) Interim Report: Revenue from comprehensive health services increased by 273.5%, and medical AI is being applied at an accelerated pace
China Express (03969) announced interim results, net profit of about 1,473 billion yuan, a year-on-year decrease of 9.07%
Lixun Precision (02475) announced interim results, net profit of about 7.843 billion yuan, an increase of 18.04% year-on-year
Kaisa Yemei (02168) announced interim results. Profit attributable to shareholders of 41.883 million yuan decreased by 12.4% year-on-year
China Ship Leasing (03877) announced interim results. Shareholders should account for profit of HK$1,222 billion, an increase of 10.6% over the previous year
Pharmaceutical Federation (02268) announced the interim results of the adjusted net profit attributable to company owners of about 1,027 billion yuan, an increase of 37.4% year-on-year
Xiaopeng Group-W (09868) announced interim results, net loss attributable to shareholders of 3.121 billion yuan, an increase of 173.35% year-on-year
Huiliang Technology (01860) announced 2026 interim results: revenue of US$1,156 billion, an increase of 23.2 percent year-on-year
Zero Sports Auto (09863) announced interim results. Profit attributable to shareholders of 208 million yuan increased 530.97% year over year
China Civil Aviation Information Network (00696) announced interim results. Net profit of 1,543 billion yuan to mother increased 6.59% year over year
Ming Ming is very busy (01768) released interim results. Profit to mother of 2.24 billion yuan increased by 155.39% year on year
Yuexiu Services (06626) released interim results. Shareholders should account for a profit of 224 million yuan to comprehensively optimize the layout of value-added services
China Resources Pharmaceutical (03320) announced interim results. Shareholders should account for profit of 2.287 billion yuan, an increase of 5.3% over the previous year
Sega Xinneng (06656) announced interim results, adjusted net profit of about 2,485 billion yuan, a year-on-year increase of 135.8%